Pricing

Lyell Immunopharma Inc (LYEL)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Elizabeth Homans
Employees:
270
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
650 695-0677
Lyell Immunopharma, Inc. engages in developing T cell therapies for patients with solid tumors. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers. The company entered into research and development collaboration with GlaxoSmithKline for NY-ESO-1 program.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available